InspireMD, Inc.
NSPR- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001433607
In the last 90 days, InspireMD, Inc. insiders filed 5 open-market purchases and 0 sales; 38 institutions reported holding it in 13F filings for Q3 2026, worth $14.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:20 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $48.8M (543.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 18, 2026 | Mar 12, 2025 | – | Mar 30, 2023 | – |
| Revenue | $8.98M | $7.01M | $6.21M | $5.17M | $4.50M |
| Cost of revenue | $6.33M | $5.50M | $4.40M | $4.05M | $3.74M |
| Gross profit | $2.65M | $1.51M | $1.81M | $1.12M | $754.0K |
| Operating expenses | $52.3M | $35.0M | $22.9M | $19.8M | $15.5M |
| Research and development | $15.0M | $13.6M | $7.98M | $7.81M | $5.16M |
| Selling, general and administrative | $20.7M | $15.3M | $11.1M | $8.36M | $7.41M |
| Operating income | -$49.6M | -$33.5M | -$21.1M | -$18.7M | -$14.7M |
| Income tax | $63.0K | $59.0K | $65.0K | $28.0K | $45.0K |
| Net income | -$48.8M | -$32.0M | -$19.9M | -$18.5M | -$14.9M |
| EPS, basic | $-0.76 | $-0.76 | $-0.82 | $-2.35 | – |
| EPS, diluted | $-0.76 | $-0.76 | $-0.82 | – | – |
| Weighted shares, basic | 64.3M | 41.9M | 24.3M | 7.87M | – |
| Weighted shares, diluted | 64.3M | 41.9M | 24.3M | – | – |
| Margins and growth | |||||
| Gross margin | 29.5% | 21.5% | 29.1% | 21.6% | 16.8% |
| Operating margin | -552.6% | -478.0% | -340.7% | -361.9% | -327.4% |
| Net margin | -543.3% | -456.6% | -321.0% | -357.6% | -331.9% |
| Revenue growth, year over year | +28.1% | +13.0% | +20.0% | +15.0% | +80.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 18, 2026 | Mar 12, 2025 | – | Mar 30, 2023 | – |
| Cash and equivalents | $8.94M | $18.9M | $9.64M | $4.63M | $12.0M |
| Short-term investments | $45.3M | $15.7M | $29.4M | – | – |
| Accounts receivable | $2.17M | $1.57M | $1.80M | $1.03M | $1.22M |
| Inventory | $3.40M | $2.57M | $2.11M | $1.62M | $1.14M |
| Total current assets | $61.5M | $40.5M | $44.2M | $21.3M | $37.1M |
| Property, plant and equipment | $3.58M | $2.37M | $1.06M | $917.0K | $632.0K |
| Total assets | $69.4M | $46.8M | $47.6M | $24.7M | $39.7M |
| Total current liabilities | $10.7M | $7.68M | $6.02M | $5.07M | $4.35M |
| Total liabilities | $14.2M | $10.7M | $8.14M | $7.26M | $6.18M |
| Shareholders' equity | $55.2M | $36.1M | $39.5M | $17.4M | $33.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 18, 2026 | Mar 12, 2025 | – | Mar 30, 2023 | – |
| Operating cash flow | -$35.1M | -$21.9M | -$16.4M | -$15.5M | -$13.2M |
| Capital expenditures | $1.66M | $1.40M | $381.0K | $473.0K | $344.0K |
| Free cash flow | -$36.8M | -$23.3M | -$16.8M | -$16.0M | -$13.6M |
| Depreciation and amortization | $476.0M | $280.0M | $232.0M | $188.0K | $161.0K |
| Stock-based compensation | $12.3M | $10.1M | $4.49M | $2.35M | $1.58M |
| Investing cash flow | -$30.6M | $12.6M | -$16.1M | $8.44M | -$22.5M |
| Financing cash flow | $55.6M | $18.5M | $37.5M | -$140.0K | $35.0M |
| Net change in cash | -$9.98M | $9.28M | $5.01M | -$7.37M | -$641.0K |
| Ratio | |||||
| Stock-based compensation, % of revenue | 137.3% | 144.6% | 72.4% | 45.5% | 35.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 16, 2026 | 54.1M | +27.7% | SEC |
| Aug 14, 2026 | 46.5M | +11.4% | SEC |
| May 7, 2026 | 46.8M | +52.9% | SEC |
| Mar 18, 2026 | 46.8M | +57.6% | SEC |
| Nov 10, 2025 | 42.4M | +62.4% | SEC |
| Aug 4, 2025 | 41.7M | +62.3% | SEC |
| May 8, 2025 | 30.6M | +22.9% | SEC |
| Mar 12, 2025 | 29.7M | +26.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q2 2021.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.